Results 141 to 150 of about 2,156 (171)

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.

Journal of Clinical Oncology, 1998
Slawomir Wojtowicz‐Praga, Jeff Torri, Michael D. Johnson, VM Steen, John B. Marshall, Elizabeth Ness, Rita A. Dickson, Mark Sale, H. S. Rasmussen, Thomas A. Chiodo, Michael Hawkins   +10 more
openalex   +2 more sources

Batimastat and Marimastat in Cancer: Summary of Early Clinical Data

, 2003
Henrik Rasmussen
openalex   +2 more sources

Studies of a Cobalt(III) Complex of the MMP Inhibitor Marimastat: A Potential Hypoxia‐Activated Prodrug

Chemistry, 2006
Timothy W. Failes, Carleen Cullinane, Connie I. Diakos, Natsuho Yamamoto, J. Guy Lyons, Trevor W. Hambley   +5 more
openalex   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

ChemInform Abstract: Five‐Component Synthesis of Marimastat Analogues.

ChemInform, 1999
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
S. PATEL, L. SAROGLOU, C. D. FLOYD, A. MILLER, M. WHITTAKER   +4 more
openaire   +1 more source

Marimastat trial results

Trends in Biotechnology, 2001
Marimastat, the matrix-metalloproteinase inhibitor developed by British Biotech (Oxford, UK), produces survival rates comparable to chemotherapy in patients suffering from non-metastatic pancreatic cancer (Journal of Clinical Oncology, 1 August). When trialled against the chemotherapeutic agent gemcitabine, one-year survival rates for patients taking ...
openaire   +1 more source

Ras-transfection up-regulated HaCaT cell migration: Inhibition by Marimastat

Clinical & Experimental Metastasis, 1999
Cell migration is an essential process in physiological and pathological conditions such as wound healing and tumor invasion. This phenomenon involves cell adhesion on the extracellular matrix mediated by integrins, and cell detachment promoted in part by metalloproteinases (MMPs). In the present study, the migration of two HaCaT-ras clones (metastatic
S, Charvat, C, Le Griel, M C, Chignol, D, Schmitt, M, Serres   +4 more
openaire   +2 more sources

Batimastat and Marimastat in Cancer

1999
Batimastat® and Marimastat® are broad-spectrum matrix metalloproteinase inhibitors (MMPI) with potent activity against most of the major matrix metalloproteinases (MMPs). Batimastat is the prototype MMPI, and is highly active against interstitial collagenase (MMP-1) (IC50 = 3 nM), stomelysin-1 (MMP-3) (IC50 = 20 nM), gelatinase-A (MMP-2) (IC50 = 4 nM),
openaire   +1 more source

Metalloelastase (MMP-12) induced inflammatory response in mice airways: Effects of dexamethasone, rolipram and marimastat

European Journal of Pharmacology, 2007
Direct instillation of a recombinant human form of MMP-12 (rhMMP-12) in mice airways elicited an early inflammatory response characterized by neutrophil influx, cytokine release and gelatinase activation followed by a delayed response, mainly characterized by macrophage recruitment.
Soazig, Nénan, Vincent, Lagente, Jean-Michel, Planquois, Simon, Hitier, Patrick, Berna, Claude P, Bertrand, Elisabeth, Boichot   +6 more
openaire   +2 more sources

Towards bioreductively activated prodrugs: Fe(III) complexes of hydroxamic acids and the MMP inhibitor marimastat

Journal of Inorganic Biochemistry, 2007
Fe(III)-salen (N,N-bis(salicylidene)-ethane-1,2-diimine) complexes of simple hydroxamic acids and the MMP (matrix metalloproteinase) inhibitor marimastat have been evaluated as hypoxia activated drug carriers. The aceto- (aha), propion- (pha), benzohydroxamato (bha), and marimastat complexes were prepared and characterised by single crystal X-ray ...
Timothy W, Failes, Trevor W, Hambley
openaire   +2 more sources

Effect of marimastat on serum tumour markers in patients with colorectal cancer.

International journal of surgical investigation, 2003
Matrix metalloproteinases (MMPs) are a family of enzymes that break down extra cellular matrix proteins during tissue formation. Tumours have been shown to over-express certain matrix metalloproteinases relative to normal tissue. Matrix metalloproteinases are associated with the disruption of tissue architecture in the growth of tumours and they are ...
H, North, J, King, D L, Morris
openaire   +1 more source